Combinatorial therapies for epigenetic, immunotherapeutic, and genetic targeting of chordoma.

IF 3.2 2区 医学 Q2 CLINICAL NEUROLOGY
Journal of Neuro-Oncology Pub Date : 2025-04-01 Epub Date: 2024-12-31 DOI:10.1007/s11060-024-04920-y
Christian Godinez, Beatrice Campilan, Christian Schroeder, Jonathan Arditi, Madison J Michles, Benjamín Córdova Herrera, Kaylee Gallagher, Tati-Anna Robinson, Tyler Owens, Ziya L Gokaslan, Patricia Sullivan, Margot Martinez-Moreno
{"title":"Combinatorial therapies for epigenetic, immunotherapeutic, and genetic targeting of chordoma.","authors":"Christian Godinez, Beatrice Campilan, Christian Schroeder, Jonathan Arditi, Madison J Michles, Benjamín Córdova Herrera, Kaylee Gallagher, Tati-Anna Robinson, Tyler Owens, Ziya L Gokaslan, Patricia Sullivan, Margot Martinez-Moreno","doi":"10.1007/s11060-024-04920-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Chordoma, a rare malignancy of the axial skeleton and skull base, presents significant therapeutic challenges due to the high rates of tumor recurrence and resistance. While surgical resection and radiation therapy remain the gold standard of treatment, the lack of additional treatment options necessitates the exploration of novel therapies. Combinatorial therapies hold significant potential in shaping patient prognosis. By targeting the immunotherapeutic, epigenetic, and genetic landscapes of chordoma, these methods enable the more effective and personalized management of the diverse molecular mechanisms driving chordoma growth and resistance.</p><p><strong>Methods: </strong>To elucidate such potential, we conducted a literature review of all published articles on the usage of immunotherapeutic, epigenetic, and genetic approaches for chordoma treatment from 2014 to 2024.</p><p><strong>Results: </strong>Eighty-one papers were excluded based on our inclusion criteria. From the remaining thirty-nine publications, we found evidence supporting the efficacy of immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapies, and monoclonal antibodies; the roles of DNA methylation patterns, histone modification pathways, and miRNA regulation; and the contribution of cancer stem-like cells (CSCs) to chordoma progression.</p><p><strong>Conclusion: </strong>Our findings underscore the importance of a multidirectional approach in chordoma treatment throughout the disease progression to reduce morbidity and improve patient outcomes despite the heterogeneity of chordoma.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"307-315"},"PeriodicalIF":3.2000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-024-04920-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Chordoma, a rare malignancy of the axial skeleton and skull base, presents significant therapeutic challenges due to the high rates of tumor recurrence and resistance. While surgical resection and radiation therapy remain the gold standard of treatment, the lack of additional treatment options necessitates the exploration of novel therapies. Combinatorial therapies hold significant potential in shaping patient prognosis. By targeting the immunotherapeutic, epigenetic, and genetic landscapes of chordoma, these methods enable the more effective and personalized management of the diverse molecular mechanisms driving chordoma growth and resistance.

Methods: To elucidate such potential, we conducted a literature review of all published articles on the usage of immunotherapeutic, epigenetic, and genetic approaches for chordoma treatment from 2014 to 2024.

Results: Eighty-one papers were excluded based on our inclusion criteria. From the remaining thirty-nine publications, we found evidence supporting the efficacy of immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapies, and monoclonal antibodies; the roles of DNA methylation patterns, histone modification pathways, and miRNA regulation; and the contribution of cancer stem-like cells (CSCs) to chordoma progression.

Conclusion: Our findings underscore the importance of a multidirectional approach in chordoma treatment throughout the disease progression to reduce morbidity and improve patient outcomes despite the heterogeneity of chordoma.

脊索瘤的表观遗传、免疫治疗和遗传靶向治疗的组合疗法。
目的:脊索瘤是一种罕见的中轴骨和颅底恶性肿瘤,由于肿瘤的高复发率和耐药性,给治疗带来了重大挑战。虽然手术切除和放射治疗仍然是治疗的金标准,但缺乏额外的治疗选择需要探索新的治疗方法。联合治疗在塑造患者预后方面具有重要的潜力。通过针对脊索瘤的免疫治疗、表观遗传学和遗传景观,这些方法能够更有效和个性化地管理驱动脊索瘤生长和耐药性的各种分子机制。方法:为了阐明这种潜力,我们对2014年至2024年所有发表的关于免疫治疗、表观遗传学和遗传学方法用于脊索瘤治疗的文章进行了文献综述。结果:根据我们的纳入标准,81篇论文被排除。从剩下的39篇出版物中,我们发现了支持免疫检查点抑制剂(ICIs)、嵌合抗原受体(CAR) t细胞疗法和单克隆抗体有效性的证据;DNA甲基化模式、组蛋白修饰途径和miRNA调控的作用;以及癌症干细胞(CSCs)对脊索瘤进展的贡献。结论:我们的研究结果强调了在脊索瘤的整个疾病进展过程中多向治疗的重要性,尽管脊索瘤具有异质性,但它可以降低发病率并改善患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Neuro-Oncology
Journal of Neuro-Oncology 医学-临床神经学
CiteScore
6.60
自引率
7.70%
发文量
277
审稿时长
3.3 months
期刊介绍: The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信